Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial

The Lancet Oncology 2026

View at publisher
Authors: Hua Zhong, Jing Wang, Runxiang Yang, Yongzhong Luo, Wei Zuo, Wei Zhang, Chao Xie, Qingshan Li, Qiang Liu, Xingxiang Xu, Qiming Wang, Yan Yu
+14 more Yongxing Chen, Tienan Yi, Xuhong Min, Jinsheng Shi, Jian Yang, Hongmei Sun, Hualin Chen, Huaqiu Shi, Junzhen Gao, Jianhua Shi, Bo Zhang, Tianqing Chu, Kai Li, Baohui Han
DOI: 10.1016/s1470-2045(26)00049-5
Cited by: 5
References: 27

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Lung Cancer Research Studies Lung Cancer Treatments and Mutations

Publication details

Journal / source
The Lancet Oncology
Publisher
Elsevier BV
Volume
27
Issue
4
Pages
419–431
Publication date
10 March 2026
Language
EN